Dr Jamie Mann

Dr Jamie Mann is a postdoctoral research scientist working within Professor Robin Shattock's Mucosal Infection and Immunity group. He initially attended the University of Strathclyde in Glasgow where he undertook a joint honours degree in Immunology and Microbiology before completing his PhD in the department of Immunology in 2006. For his PhD thesis, Jamie investigated "Oral Vaccine Delivery Systems" under the supervisions of Dr Valerie Ferro, Prof James Alexander and Prof William Stimson. Here he applied novel Bilosome technologies for the successful delivery of various vaccine candidates, such as influenza hemagglutinin, via the oral route. On completing his PhD, Jamie moved to London to take up his first postdoctoral position under the supervisions of Dr Paul Mckay and Prof. Martin Cranage. During this time he investigated methods to optimise mucosal based vaccination against mucosally acquired HIV-1 infection. By exploiting receptor-ligand interactions involved in transcytosis, he was able to substantially increase vaccine antigen uptake across intact mucosal epithelia resulting in significantly augmented immune responses. This was achieved by utilising apically expressed receptors such as CD71 and its ligand Transferrin, conjugated to a model HIV-1 CN54gp140 vaccine antigen. In 2011 Jamie moved to Imperial College where his research priorities focused on understanding the fundamentals of basic mucosal vaccinology as well as preclinical vaccine development with emphasis on DNA delivery. Jamie is currently employed by CUT’HIVAC (cutaneous and mucosal HIV vaccination), a European FP7 funded consortium, to evaluate topical mucosal delivery of a plasmid vector designed for delivery of HIV-1 vaccine candidates.